Ocular Therapeutix To Report Fourth Quarter And Full Year 2016 Financial Results
BEDFORD, Mass--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2016, on Friday, March 10, 2017. Following distribution of the earnings release via wire services, the Ocular management team will host a live conference call and webcast at 8:30 a.m. Eastern Time to review the Company’s financial results and provide a general business update.
The live webcast can be accessed by visiting the investor section of Ocular’s website at investors.ocutx.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call 844-464-3934 (U.S.) or 765-507-2620 (International) to listen to the conference call. The conference ID number for the live call will be 77324558. An archive of the webcast will be available until March 24, 2017 on the company’s website.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Ocular Therapeutix has resubmitted a new drug application (NDA) for post-surgical pain for its lead product candidate, DEXTENZA (dexamethasone insert), which has completed Phase 3 clinical development for ocular pain and inflammation following ophthalmic surgery, and the Company is pursuing additional indications for DEXTENZA. OTX-TP (sustained release travoprost) is in Phase 3 clinical development for glaucoma and ocular hypertension. Ocular Therapeutix is also evaluating injectable drug delivery depots for back-of-the-eye diseases. Ocular Therapeutix's first product, ReSure® Sealant, is FDA-approved to seal corneal incisions following cataract surgery.